Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1D1 | P20393 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.37 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.35 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.35 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22183226 | 1.00 | NR1D1 (0.40) | NR1D1EPHX2EPHX1LIMK2BRD4 | |
| SCHEMBL12506857 | 0.91 | CYP4F2 (0.38) | NR1D1EPHX2EPHX1BRD4 | |
| SCHEMBL13003572 | 0.88 | LIMK2 (0.43) | EPHX2EPHX1LIMK2CYP1A2TDP1 | |
| SCHEMBL20060297 | 0.86 | NR1D1 (0.37) | NR1D1EPHX2EPHX1LIMK2BRD4 | |
| SCHEMBL12522301 | 0.86 | CHRNB2 (0.43) | EPHX2EPHX1CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL20702384 | 0.85 | TACR3 (0.37) | — | |
| SCHEMBL4328443 | 0.85 | TACR3 (0.37) | — | |
| SCHEMBL20702387 | 0.85 | TACR3 (0.37) | — | |
| SCHEMBL12136949 | 0.83 | MMP1 (0.38) | NR1D1EPHX2EPHX1LIMK2BRD4 | |
| SCHEMBL24127262 | 0.83 | MAPT (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827641-B2 | Toll-like receptor antagonist compounds and methods of use | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2023-11-28 | — | — | US | disclosed |
| WO-2022150707-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | Tabomedex Biosciences, Inc. (US) | 2022-07-14 | — | — | WO | disclosed |
| US-11370794-B2 | Toll-like receptor antagonist compounds and methods of use | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2022-06-28 | — | — | US | disclosed |
| US-20190345161-A1 | TOLL-LIKE RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USE | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2019-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827641-B2 | Toll-like receptor antagonist compounds and methods of use | TLR7, TLR9, TLR1 | NR1D1 937/4885EPHX2 3711/4885EPHX1 3320/4885 |
| US-20190345161-A1 | TOLL-LIKE RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USE | TLR7, TLR9, TLR1 | NR1D1 937/4885EPHX2 3711/4885EPHX1 3320/4885 |
| US-11370794-B2 | Toll-like receptor antagonist compounds and methods of use | TLR9, TLR7, TLR8 | NR1D1 1139/4885EPHX2 3512/4885EPHX1 3321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.